{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:44:20Z","timestamp":1778395460078,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA187060-04"],"award-info":[{"award-number":["5R01CA187060-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple primary melanoma (MPM) has been associated with a higher 10-year mortality risk compared to patients with single primary melanoma (SPM). Given that 3\u20138% of patients with SPM develop additional primary melanomas, new markers predictive of MPM risk are needed. Based on the evidence that the immune system may regulate melanoma progression, we explored whether germline genetic variants controlling the expression of 41 immunomodulatory genes modulate the risk of MPM compared to patients with SPM or healthy controls. By genotyping these 41 variants in 977 melanoma patients, we found that rs2071304, linked to the expression of <jats:italic>SPI1<\/jats:italic>, was strongly associated with MPM risk reduction (OR\u2009=\u20090.60; 95% CI\u2009=\u20090.45\u20130.81; p\u2009=\u20090.0007) when compared to patients with SPM. Furthermore, we showed that rs6695772, a variant affecting expression of BATF3, is also associated with MPM-specific survival (HR\u2009=\u20093.42; 95% CI\u2009=\u20091.57\u20137.42; p\u2009=\u20090.0019). These findings provide evidence that the genetic variation in immunomodulatory pathways may contribute to the development of secondary primary melanomas and also associates with MPM survival. The study suggests that inherited host immunity may play an important role in MPM development.<\/jats:p>","DOI":"10.1038\/s41598-019-46665-z","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T10:50:58Z","timestamp":1563187858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)"],"prefix":"10.1038","volume":"9","author":[{"given":"Robert","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexi","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-4773","authenticated-orcid":false,"given":"Leah","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vylyny","family":"Chat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Kazlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"46665_CR1","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H","volume":"67","author":"BK Gupta","year":"1991","unstructured":"Gupta, B. K., Piedmonte, M. R. & Karakousis, C. P. Attributes and survival patterns of multiple primary cutaneous malignant melanoma. Cancer 67, 1984\u20131989 (1991).","journal-title":"Cancer"},{"key":"46665_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","volume":"66","author":"U Leiter","year":"2012","unstructured":"Leiter, U. et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 66, 37\u201345, https:\/\/doi.org\/10.1016\/j.jaad.2010.09.772 (2012).","journal-title":"J Am Acad Dermatol"},{"key":"46665_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.jid.2016.03.014","volume":"136","author":"DR Youlden","year":"2016","unstructured":"Youlden, D. R. et al. Ten-Year Survival after Multiple Invasive Melanomas Is Worse than after a Single Melanoma: a Population-Based Study. J Invest Dermatol 136, 2270\u20132276, https:\/\/doi.org\/10.1016\/j.jid.2016.03.014 (2016).","journal-title":"J Invest Dermatol"},{"key":"46665_CR4","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1002\/cncr.27407","volume":"118","author":"C Hwa","year":"2012","unstructured":"Hwa, C. et al. Single versus multiple primary melanomas: old questions and new answers. Cancer 118, 4184\u20134192, https:\/\/doi.org\/10.1002\/cncr.27407 (2012).","journal-title":"Cancer"},{"key":"46665_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.294.13.1647","volume":"294","author":"CR Ferrone","year":"2005","unstructured":"Ferrone, C. R. et al. Clinicopathological features of and risk factors for multiple primary melanomas. Jama-J Am Med Assoc 294, 1647\u20131654, https:\/\/doi.org\/10.1001\/jama.294.13.1647 (2005).","journal-title":"Jama-J Am Med Assoc"},{"key":"46665_CR6","first-page":"330","volume":"113","author":"CL Slingluff Jr.","year":"1993","unstructured":"Slingluff, C. L. Jr., Vollmer, R. T. & Seigler, H. F. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 113, 330\u2013339 (1993).","journal-title":"Surgery"},{"key":"46665_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cncr.11116","volume":"97","author":"WB Goggins","year":"2003","unstructured":"Goggins, W. B. & Tsao, H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 97, 639\u2013643, https:\/\/doi.org\/10.1002\/cncr.11116 (2003).","journal-title":"Cancer"},{"issue":"3","key":"46665_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaci.2017.05.024","volume":"141","author":"Paul C. Mayor","year":"2018","unstructured":"Mayor, P. C. et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol, https:\/\/doi.org\/10.1016\/j.jaci.2017.05.024 (2017).","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"46665_CR9","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1001\/jamadermatol.2017.1716","volume":"153","author":"MM Asgari","year":"2017","unstructured":"Asgari, M. M., Ray, G. T., Quesenberry, C. P. Jr., Katz, K. A. & Silverberg, M. J. Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatol 153, 892\u2013896, https:\/\/doi.org\/10.1001\/jamadermatol.2017.1716 (2017).","journal-title":"JAMA Dermatol"},{"key":"46665_CR10","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/hmg\/ddt142","volume":"22","author":"M Zhang","year":"2013","unstructured":"Zhang, M. et al. Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. Human molecular genetics 22, 2948\u20132959, https:\/\/doi.org\/10.1093\/hmg\/ddt142 (2013).","journal-title":"Human molecular genetics"},{"key":"46665_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/ng.958","volume":"43","author":"S Macgregor","year":"2011","unstructured":"Macgregor, S. et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature genetics 43, 1114\u20131118, https:\/\/doi.org\/10.1038\/ng.958 (2011).","journal-title":"Nature genetics"},{"key":"46665_CR12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/ng.959","volume":"43","author":"JH Barrett","year":"2011","unstructured":"Barrett, J. H. et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nature genetics 43, 1108\u20131113, https:\/\/doi.org\/10.1038\/ng.959 (2011).","journal-title":"Nature genetics"},{"key":"46665_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/ng.411","volume":"41","author":"DT Bishop","year":"2009","unstructured":"Bishop, D. T. et al. Genome-wide association study identifies three loci associated with melanoma risk. Nature genetics 41, 920\u2013925, https:\/\/doi.org\/10.1038\/ng.411 (2009).","journal-title":"Nature genetics"},{"key":"46665_CR14","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1093\/hmg\/ddr415","volume":"20","author":"CI Amos","year":"2011","unstructured":"Amos, C. I. et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human molecular genetics 20, 5012\u20135023, https:\/\/doi.org\/10.1093\/hmg\/ddr415 (2011).","journal-title":"Human molecular genetics"},{"key":"46665_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/jid.2012.75","volume":"132","author":"MH Law","year":"2012","unstructured":"Law, M. H., Macgregor, S. & Hayward, N. K. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol 132, 1763\u20131774, https:\/\/doi.org\/10.1038\/jid.2012.75 (2012).","journal-title":"J Invest Dermatol"},{"key":"46665_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/carcin\/bgi252","volume":"27","author":"RC Millikan","year":"2006","unstructured":"Millikan, R. C. et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis 27, 610\u2013618, https:\/\/doi.org\/10.1093\/carcin\/bgi252 (2006).","journal-title":"Carcinogenesis"},{"key":"46665_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1055-9965.EPI-14-1426","volume":"24","author":"DC Gibbs","year":"2015","unstructured":"Gibbs, D. C. et al. Inherited genetic variants associated with occurrence of multiple primary melanoma. Cancer Epidemiol Biomarkers Prev 24, 992\u2013997, https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-1426 (2015).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"46665_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/exd.12382","volume":"23","author":"Z Hatvani","year":"2014","unstructured":"Hatvani, Z. et al. Genotype analysis in Hungarian patients with multiple primary melanoma. Experimental dermatology 23, 361\u2013364, https:\/\/doi.org\/10.1111\/exd.12382 (2014).","journal-title":"Experimental dermatology"},{"key":"46665_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/gcc.21952","volume":"51","author":"P Helsing","year":"2012","unstructured":"Helsing, P. et al. MC1R, ASIP, TYR, and TYRP1 gene variants in a population-based series of multiple primary melanomas. Genes Chromosomes Cancer 51, 654\u2013661, https:\/\/doi.org\/10.1002\/gcc.21952 (2012).","journal-title":"Genes Chromosomes Cancer"},{"key":"46665_CR20","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-06-1634","volume":"66","author":"PA Kanetsky","year":"2006","unstructured":"Kanetsky, P. A. et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 66, 9330\u20139337, https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1634 (2006).","journal-title":"Cancer Res"},{"key":"46665_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaad.2015.09.053","volume":"74","author":"W Bruno","year":"2016","unstructured":"Bruno, W. et al. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. J Am Acad Dermatol 74, 325\u2013332, https:\/\/doi.org\/10.1016\/j.jaad.2015.09.053 (2016).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"46665_CR22","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.canep.2011.03.003","volume":"35","author":"Rochelle Mandelcorn-Monson","year":"2011","unstructured":"Mandelcorn-Monson, R. Sun Exposure, Vitamin D Receptor Polymorphisms FokI and BsmI and Risk of Multiple Primary Melanoma. 35, e105\u2013110, https:\/\/doi.org\/10.1016\/j.canep.2011.03.003 (2011).","journal-title":"Cancer Epidemiology"},{"key":"46665_CR23","doi-asserted-by":"publisher","first-page":"e1002003","DOI":"10.1371\/journal.pgen.1002003","volume":"7","author":"AC Nica","year":"2011","unstructured":"Nica, A. C. et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 7, e1002003, https:\/\/doi.org\/10.1371\/journal.pgen.1002003 (2011).","journal-title":"PLoS Genet"},{"key":"46665_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-279","volume":"11","author":"J Rendleman","year":"2013","unstructured":"Rendleman, J. et al. Melanoma risk loci as determinants of melanoma recurrence and survival. Journal of translational medicine 11, 279, https:\/\/doi.org\/10.1186\/1479-5876-11-279 (2013).","journal-title":"Journal of translational medicine"},{"key":"46665_CR25","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.ccr-15-2066","volume":"22","author":"M Vogelsang","year":"2016","unstructured":"Vogelsang, M. et al. The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research 22, 3268\u20133280, https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2066 (2016).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"46665_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/jmedgenet-2014-102832","volume":"52","author":"J Rendleman","year":"2015","unstructured":"Rendleman, J. et al. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. J Med Genet 52, 231\u2013239, https:\/\/doi.org\/10.1136\/jmedgenet-2014-102832 (2015).","journal-title":"J Med Genet"},{"key":"46665_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/cmr.0000000000000015","volume":"23","author":"M Qian","year":"2013","unstructured":"Qian, M. et al. Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. Melanoma research 23, 461\u2013467, https:\/\/doi.org\/10.1097\/cmr.0000000000000015 (2013).","journal-title":"Melanoma research"},{"key":"46665_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ng.2394","volume":"44","author":"E Grundberg","year":"2012","unstructured":"Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nature genetics 44, 1084\u20131089, https:\/\/doi.org\/10.1038\/ng.2394 (2012).","journal-title":"Nature genetics"},{"key":"46665_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1375\/183242706779462462","volume":"9","author":"TD Spector","year":"2006","unstructured":"Spector, T. D. & Williams, F. M. The UK Adult Twin Registry (TwinsUK). Twin research and human genetics: the official journal of the International Society for Twin Studies 9, 899\u2013906, https:\/\/doi.org\/10.1375\/183242706779462462 (2006).","journal-title":"Twin research and human genetics: the official journal of the International Society for Twin Studies"},{"key":"46665_CR30","doi-asserted-by":"publisher","first-page":"e1003220","DOI":"10.1371\/journal.pgen.1003220","volume":"9","author":"J Vijai","year":"2013","unstructured":"Vijai, J. et al. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet 9, e1003220, https:\/\/doi.org\/10.1371\/journal.pgen.1003220 (2013).","journal-title":"PLoS Genet"},{"key":"46665_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81, 559\u2013575, https:\/\/doi.org\/10.1086\/519795 (2007).","journal-title":"American journal of human genetics"},{"key":"46665_CR32","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1177\/000313481608201034","volume":"82","author":"MS Jones","year":"2016","unstructured":"Jones, M. S. et al. Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surgeon 82, 1009\u20131013 (2016).","journal-title":"Am Surgeon"},{"key":"46665_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711\u2013723, https:\/\/doi.org\/10.1056\/NEJMoa1003466 (2010).","journal-title":"N Engl J Med"},{"key":"46665_CR34","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372, 2521\u20132532, https:\/\/doi.org\/10.1056\/NEJMoa1503093 (2015).","journal-title":"N Engl J Med"},{"key":"46665_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New Engl J Med 372, 320\u2013330, https:\/\/doi.org\/10.1056\/NEJMoa1412082 (2015).","journal-title":"New Engl J Med"},{"key":"46665_CR36","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377, 1824\u20131835, https:\/\/doi.org\/10.1056\/NEJMoa1709030 (2017).","journal-title":"N Engl J Med"},{"key":"46665_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","volume":"87","author":"AW Kubica","year":"2012","unstructured":"Kubica, A. W. & Brewer, J. D. Melanoma in immunosuppressed patients. Mayo Clin Proc 87, 991\u20131003, https:\/\/doi.org\/10.1016\/j.mayocp.2012.04.018 (2012).","journal-title":"Mayo Clin Proc"},{"key":"46665_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","volume":"148","author":"P Patel","year":"2008","unstructured":"Patel, P. et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148, 728\u2013736 (2008).","journal-title":"Ann Intern Med"},{"issue":"2","key":"46665_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2004.11.060","volume":"54","author":"Karl Wilkins","year":"2006","unstructured":"Wilkins, K. et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 54, 189\u2013206; quiz 207\u2013110, https:\/\/doi.org\/10.1016\/j.jaad.2004.11.060 (2006).","journal-title":"Journal of the American Academy of Dermatology"},{"key":"46665_CR40","doi-asserted-by":"publisher","first-page":"3145986","DOI":"10.1155\/2016\/3145986","volume":"2016","author":"L Juul Nielsen","year":"2016","unstructured":"Juul Nielsen, L. & Rosenkrantz Holmich, L. Eleven Primary Melanomas, Colon Cancer, and Atypical Nevi in the Same Patient: A Case Report and Literature Review. Case Rep Dermatol Med 2016, 3145986, https:\/\/doi.org\/10.1155\/2016\/3145986 (2016).","journal-title":"Case Rep Dermatol Med"},{"key":"46665_CR41","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.8079170","volume":"265","author":"EW Scott","year":"1994","unstructured":"Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573\u20131577 (1994).","journal-title":"Science"},{"key":"46665_CR42","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1002\/j.1460-2075.1996.tb00949.x","volume":"15","author":"SR McKercher","year":"1996","unstructured":"McKercher, S. R. et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 15, 5647\u20135658 (1996).","journal-title":"EMBO J"},{"key":"46665_CR43","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4049\/jimmunol.164.4.1855","volume":"164","author":"KL Anderson","year":"2000","unstructured":"Anderson, K. L. et al. Transcription factor PU.1 is necessary for development of thymic and myeloid progenitor-derived dendritic cells. J Immunol 164, 1855\u20131861 (2000).","journal-title":"J Immunol"},{"key":"46665_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","volume":"31","author":"M Merad","year":"2013","unstructured":"Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31, 563\u2013604, https:\/\/doi.org\/10.1146\/annurev-immunol-020711-074950 (2013).","journal-title":"Annu Rev Immunol"},{"key":"46665_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng1679","volume":"38","author":"F Rosenbauer","year":"2006","unstructured":"Rosenbauer, F. et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nature genetics 38, 27\u201337, https:\/\/doi.org\/10.1038\/ng1679 (2006).","journal-title":"Nature genetics"},{"key":"46665_CR46","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4049\/jimmunol.1102107","volume":"188","author":"SV Kaveri","year":"2012","unstructured":"Kaveri, S. V., Silverman, G. J. & Bayry, J. Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential. Journal of Immunology 188, 939\u2013945, https:\/\/doi.org\/10.4049\/jimmunol.1102107 (2012).","journal-title":"Journal of Immunology"},{"key":"46665_CR47","doi-asserted-by":"publisher","unstructured":"Alivernini, S. et al. MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nat Commun 7, https:\/\/doi.org\/10.1038\/ncomms12970 (2016).","DOI":"10.1038\/ncomms12970"},{"key":"46665_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15384047.2017.1323596","volume":"18","author":"F Mahmoud","year":"2017","unstructured":"Mahmoud, F. et al. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol Ther 18, 451\u2013469, https:\/\/doi.org\/10.1080\/15384047.2017.1323596 (2017).","journal-title":"Cancer Biol Ther"},{"key":"46665_CR49","doi-asserted-by":"crossref","unstructured":"Wang, J. M., Lai, M. Z. & Yang-Yen, H. F. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol 23, 1896-1909 (2003).","DOI":"10.1128\/MCB.23.6.1896-1909.2003"},{"key":"46665_CR50","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/0008-5472.CAN-08-0349","volume":"68","author":"CC Jiang","year":"2008","unstructured":"Jiang, C. C. et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68, 6708\u20136717, https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0349 (2008).","journal-title":"Cancer Res"},{"key":"46665_CR51","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100, https:\/\/doi.org\/10.1126\/science.1164206 (2008).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46665-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46665-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46665-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:31:51Z","timestamp":1671276711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46665-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46665"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46665-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"25 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflict of interest, except for: David Polsky serves as a consultant at Novartis and MolecularMD and received research support from Novartis and Bio-Rad.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10173"}}